Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul;66(1):133-46.
doi: 10.1053/j.ajkd.2015.01.034. Epub 2015 May 7.

Calciphylaxis: risk factors, diagnosis, and treatment

Sagar U Nigwekar  1 , Daniela Kroshinsky  2 , Rosalynn M Nazarian  3 , Jeremy Goverman  4 , Rajeev Malhotra  5 , Vicki Ann Jackson  6 , Mihir M Kamdar  6 , David J R Steele  7 , Ravi I Thadhani  7
Affiliations
Review

Calciphylaxis: risk factors, diagnosis, and treatment

Sagar U Nigwekar et al. Am J Kidney Dis. 2015 Jul.

Abstract

Calciphylaxis is a rare but devastating condition that has continued to challenge the medical community since its early descriptions in the scientific literature many decades ago. It is predominantly seen in patients with chronic kidney failure treated with dialysis (uremic calciphylaxis) but is also described in patients with earlier stages of chronic kidney disease and with normal kidney function. In this review, we discuss the available medical literature regarding risk factors, diagnosis, and treatment of both uremic and nonuremic calciphylaxis. High-quality evidence for the evaluation and management of calciphylaxis is lacking at this time due to its rare incidence and poorly understood pathogenesis and the relative paucity of collaborative research efforts. We hereby provide a summary of recommendations developed by a multidisciplinary team for patients with calciphylaxis.

Keywords: Calcific uremic arteriolopathy; calciphylaxis; review; risk factors; sodium thiosulfate; warfarin.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Morphology of calciphylaxis lesions
Figure 2
Figure 2. Histopathology of calciphylaxis
Course basophilic medial calcification of small arteries as demonstrated by Hematoxylin & Eosin stain (400×) and highlighted by von Kossa histochemical stain (200×) (Panel A-B). Septal panniculitis and subcutaneous fat necrosis with presence of subtle finely granular basophilic calcium deposits (400×, Hematoxylin & Eosin, Panel C). A von Kossa histochemical stain aids in the detection of interstitial calcium deposits, which may not be identified on routine histologic sections (200×, Panel D).
Figure 3
Figure 3. Professor Selye's experimental calciphylaxis model
See this image and copyright information in PMC

References

    1. Selye H, Gentile G, Prioreschi P. Cutaneous molt induced by calciphylaxis in the rat. Science. 1961;134(3493):1876–1877. - PubMed
    1. Rees JK, Coles GA. Calciphylaxis in man. British medical journal. 1969;2(5658):670–672. - PMC - PubMed
    1. Skalnik J, Vasku J, Urbanek E. Calciphylaxis and cerebral atrophy in man. Clinical orthopaedics and related research. 1970;69:172–180. - PubMed
    1. Anderson DC, Stewart WK, Piercy DM. Calcifying panniculitis with fat and skin necrosis in a case of uraemia with autonomous hyperparathyroidism. Lancet. 1968;2(7563):323–325. - PubMed
    1. Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. Journal of the American Society of Nephrology : JASN. 1996;7(7):978–982. - PubMed

MeSH terms